Comparison of Two Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Qualia NAD⁺ version 1, Qualia NAD⁺ version 2, Placebo.
- Who it may be relevant to
- Registry conditions: NAD, NAD+ Levels in the Blood. Basic parameters: 35 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Comparison of Two Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels: A Randomized, Double-Blind, Placebo-Controlled Three-Arm Trial
Overview
This is a randomized, double-blind, placebo-controlled, parallel-group study evaluating the effects of two distinct Qualia NAD⁺ formulations on intracellular NAD⁺ levels in healthy adults aged 35-75 years. Approximately 180 participants will be randomized to one of three study arms: Qualia NAD⁺ version 1, Qualia NAD⁺ version 2, or placebo. Each participant will take two capsules of their assigned product once daily in the morning, with or without food, over a 28-day period. The primary outcome is the change in intracellular NAD⁺ levels, assessed via at-home finger-stick blood collection at baseline and study completion. Secondary endpoints include changes in aging-related symptoms (AMFS scores), health-related quality of life (RAND SF-36), and evaluation of safety and tolerability. All assessments, including electronic questionnaires, are completed remotely without in-person visits.
Interventions
- Dietary supplement Qualia NAD⁺ version 1
Qualia NAD+ version 1 manufactured by Qualia Life Sciences - Dietary supplement Qualia NAD⁺ version 2
Qualia NAD+ version 2 manufactured by Qualia Life Sciences - Dietary supplement Placebo
Rice Flour
Primary outcome measures
- Between-group change in intracellular NAD⁺ levels [Time frame: 28 days]
Secondary outcome measures (4)
- Aging-Related Symptoms (AMFS scores) [Time frame: 4 weeks]
- RAND SF-36 Scale Scores [Time frame: 4 weeks]
- Side effect profile as measured by a custom Safety and Tolerability survey [Time frame: Week 1, 2, 3, and 4]
- Within-group differences in the change in intracellular NAD⁺ levels [Time frame: 4 weeks]
Eligibility criteria
Inclusion criteria
Provide voluntary, written, informed consent to participate in the study Agree to provide a valid cell phone number and are willing to receive communications through text Can read and write English Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly Willing to complete questionnaires, records, and diaries associated with the study.
Healthy male and female participants aged 35-75 years Willing to self-administer the intracellular NAD⁺ finger-stick test at home (baseline and Day 28) Willing to avoid supplements, energy drinks/shots, or other products containing niacin, niacinamide, nicotinamide riboside, or NMN for ≥ 2 weeks before baseline and throughout the study
Exclusion criteria
Women who are pregnant, breastfeeding, or planning to become pregnant during the trial Known food intolerances/allergy to any ingredients in the product Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer Having had a significant cardiovascular event in the past 6 months Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines On immunosuppressive therapy Individuals who were deemed incompatible with the test protocol Adults lacking capacity to consent
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Triple blind
- Primary purpose
- Other
Study locations
United States · 1 center
- Qualia Life Sciences — Carlsbad
Identifiers
NCT: NCT07132801 · QLS-014